KLK3 and prostate carcinoma: In the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) analyses, DRE performance deteriorated most significantly at low PSA levels [22,27].